SC-57461A

SC-57461A is a potent, orally active, and selective small molecule inhibitor of leukotriene A4 (LTA4) hydrolase. Developed by Searle (later Pfizer), it functions by blocking the enzymatic conversion of LTA4 into leukotriene B4 (LTB4), a powerful chemoattractant and activator of neutrophils and other inflammatory cells. By reducing LTB4 levels, SC-57461A aims to mitigate inflammatory responses in conditions such as rheumatoid arthritis, inflammatory bowel disease, and asthma. Although it demonstrated significant efficacy in preclinical models and early clinical studies, its development was largely discontinued in favor of other candidates.

Other names

[[3-[[4-(4-fluorophenyl)-2-thiazolyl]methoxy]phenyl]amino]oxo-acetic acid